Queensland (Affix identification label here) Government URN: Management of Diabetic Family name: Ketoacidosis in Adults Given name(s):								
Ketoacidosis in Adults Family name:								
	Given name(s):							
Date of birth: Sex: M	F II							
WARNING								
Diabetic Ketoacidosis carries a significant mortality rate and close monitoring is esse	ential.							
IF THERE IS A SUSPICION OF CEREBRAL OEDEMA OR THE PATIENT IS NOT IMF								
CALL A CONSULTANT.								
Signs of cerebral oedema (see page 4) should be monitored throughout the first 24								
This protocol is to be used for the management of Diabetic Ketoacidosis in adults over the This protocol is <i>NOT</i> to be used for the treatment of;	age of 16							
Protocol Use Hyperglycaemic Hyperosmolar State (HHS/HONK)								
The management of Diabetic Ketoacidosis in an Intensive Care Unit								
Usually a history of Type 1 Diabetes with:								
Definition of • Ketonemia/Ketonuria								
 DKA Metabolic acidosis (pH less than 7.35, bicarbonate (HCO₃) less than 15) Usually with hyperglycaemia 								
Hyperventilation								
Clinical Signs • Dehydration								
& Symptoms • Abdominal pain								
Impaired consciousness Refer to ICU for consultation if:								
pH less than 7.1								
• Altered level of consciousness								
 Consultation Severe Hypokalemia (less than 3mmol/L) Severe Hyponatremia (less than 125mmol/L) 								
Altered blood pressure/severe dehydration								
Initial fluid management								
• Early potassium replacement								
 Early IV insulin initiation (titrated to BGL) Frequent monitoring 								
NB: A Medical High Acuity Care Area is an ideal setting to manage DKA								
GRADING OF DIABETIC KETOACIDOSIS								
Action in DKA: Urine Ketone Level Blood Ketone Level Action if not in DKA (being monitored for risk of DKA))							
Continue Large more than 10mmol/L Moderate/ more than 1.4 mmol/L Risk of DKA, urgent medical revie								
to monitor 4-hrly until Moderate 4.1 – 10mmol/L Small 1 – 1.4 mmol/L Risk of DKA, report to medical sta glucose & ketones in 2 hours	aff. Retest blood							
Ketone free Small 0.5 - 4mmol/L Trace Less than 1mmol/L Retest blood glucose & ketones i to medical staff	n 2 hours report							
Negative Less than 0.5mmol/L Continue routine monitoring								
POTASSIUM REPLACEMENT GUIDELINES								
Maximum CONCENTRATION = 40mmol/L peripherally to prevent phlebitis								
EXCEPTION: isotonic, premixed potassium chloride 10mmol/100mL minibags (commercially prema	ade, ready to							
use) can be given peripherally. NOTE: Minibags MUST be given via an infusion pump. All potassium containing infusions must be given via an infusion pump or burette								
Action in DKA: Continue to monitor 4-hrly until Ketone free Urine Ketone Level Blood Ketone Level Action if not in DKA (being monitored for risk of DKA) Moderate/ to monitor 4-hrly until Ketone free Large more than 10mmol/L Moderate/ small more than 1.4 more than 1.4 Risk of DKA, urgent medical review Wo glucose & ketones in 2 hours Small 0.5 - 4mmol/L Small 1 – 1.4 mmol/L Retest blood glucose & ketones in 2 hours report to medical staff Retest blood glucose & ketones in 2 hours report to medical staff Negative Less than 0.5mmol/L Continue routine monitoring Continue routine monitoring POTASSIUM REPLACEMENT GUIDELINES Maximum CONCENTRATION = 40mmol/L peripherally to prevent phlebitis EXCEPTION: isotonic, premixed potassium chloride 10mmol/100mL minibags (commercially premade, ready to use) can be given peripherally. NOTE: Minibags MUST be given via an infusion pump. All potassium containing infusions must be given via an infusion pump or burette Maximum RATE: - With burette = 10mmol/hr With infusion pump = 20mmol/hr With infusion pump = 20mmol/hr If maximum rates or concentration are exceeded, cardiac monitoring in a high acuity bed, as well as administration through a large vein with high blood flow (eg. CVC, venous access port, PICC) is required For further information on Potassium replacement please refer to the Medication Services Queensland Prescribing Guidelines on								
	- With infusion pump = 20mmol/hr If maximum rates or concentration are exceeded, cardiac monitoring in a high acuity bed, as well as administration through a large vein with high blood flow (eg. CVC, venous access port, PICC) is required For further information on Potassium replacement please refer to the Medication Services Queensland Prescribing Guidelines on							
- With infusion pump = 20mmol/hr	intentio -							
	istration							

Prepared for Queensland Statewide Diabetes Clinical Newtork by Kunwarjit Sangla FRACP Acknowledgement to Prof Sandra Macrury

DO NOT WRITE IN THIS BINDING MARGIN

Queensland Government Management of Diabetic Ketoacidosis in Adults		does not replace clinical judgement		(Affix identification label here)					
				URN:					
				Family name:					
(Age 16 Years and Ov	ver)			Given name(s):					
				Date of birth:		Se	x: 🗌 M 🗌 F 🔲 I		
Date: Initiating MO:			Initiating MO to print patient name:						
Time Commenced:		Tick each	Tick each step as it is initiated.						
IMMEDIATE MANAGEMENT 1 st Hour (On Presentation)	ONC	OING MANAGEMENT HOURS 2 - 4	SUBSEQUENT	JBSEQUENT MANAGEMENT			CONTINUING CARE		
STEP 1 - Initial Investigation	STEP 1: Rea	assess Patient, Monitor Vital Signs	STEP 1: Reassess Pat	STEP 1: Refer For Specialist Review Before					
🗌 Two IV Cannulas	Catheter if	oliguric	Allow oral intake if bo	wel sounds present	Discharge				
☐ FBE, U&E, LFT, Blood Glucose (BGL), Venous Blood Gases	Continue 0.9%		Measure Bicarbonate within reference range	twice daily initially until	 Refer to specialist to determine Cause of DKA episode For Diabetes education and review of 				
Urine/Blood Ketones	250mls/hr f		L/hr via "Y" site when			knowledge and understanding of condition			
Blood Culture	Give 10% C	Glucose 100mL/hr via "Y" site when				STEP 2: Patient Not To Be Discharged Until			
ABG if pH less than 7.1	BGL less than	14mmol/L (second cannula)	Glucose	Insulin 10% Glucose	Normal ketones and electrolytes				
STEP 2 – Fluid Replacement	Give Potas	sium (K ⁺) infusion OVER ONE HOUR	more than 14mmol/L	6 units/hr Nil		ating normally and established on routine			
0.9% Sodium Chloride 1000mL/hr		ess anuric or K^{+} more than 5mmol/L $R_{-} = 5$ mmol/L give 10mmol/100mls		3 units/hr 100ml/hr	subcutaneous insulin				
STEP 3 – Start Insulin		: 3.5mmol/L give 2 x 10mmol/100mls	less than 9mmol/L 2 units/hr 200ml/hr			STEP3: Follow Up			
☐ Soluble, 6 units/hr IV (hold insulin until potassium is more than 3.0mmol/L – recheck hourly). In some people glucose will continue to		rther Monitoring, Continuation of Insulin	Continue 0.9% Sodium than or equal to 150mL/h reference range and pati	Arrange appropriate follow up/contact with diabetes educator and dietitian within one week of discharge					
rise requiring more insulin (to be prescribed on Insulin Infusion Chart)	Hourly BGL								
,	Continue in 14mmol/L ther	sulin 6 units/hr until BGL less than	Continue Potassium r within reference range ar	Ensure patient has a formal clinic appointment					
STEP 4 – Other Interventions		r variable rate to maintain BGL	potassium twice daily		Ensure that a copy of patient discharge letter				
🗌 Maintain airway	(9-14mmol/L)		☐ Initiate/continue long acting insulin			is sent to patient's GP and diabetes care team			
Fluid balance chart	U&Es and venous gas at end of 'hour 2' and end of		STEP 2: Continuation of Intravenous Insulin		ME	DICAL O	FFICER SIGNATURE LOG		
Commence neurological observations	'hour 4' □ Hour 2	☐ Hour 4	Measure BGL 2 hourly (hourly if BGL less than		DATE	TIME	SIGNATURE		
DVT prophylaxis			5mmol/L or more than 10)mmol/L)					
Undertake Septic screen and consider antibiotics for infection		Consider Precipitating Factors	Continue Insulin 3 uni maintain BGL (9-14mmo	its/hour or variable rate to I/L)					
Consider cardiac monitoring		Blood Cultures	When eating and biog	hemically stable, stop IV					
Consider NGT if protracted vomiting/risk of aspiration	ECG MSU	Uiral titres	fluids and convert back to	and convert back to usual subcutaneous regimen. Ensure long acting insulin is given					



Management of Diabetic Ketoacidosis in Adults (Age 16 Years and Over)

	(Affix identification label here)					
URN:						
Family name:						
Given name(s):						
Date of birth:		Sex:	М	F		

			Date of birth:			Sex:	М	🗌 F	□ I	
Date: Time treatment commenced:										
Hour										
Mental Status*										
Vital Signs					Г	n n		n	1	
Temperature										
Pulse										
Respiration (rate & depth)•										
Blood Pressure										
Chemistries									1	
Serum glucose										
Serum ketones										
Urine ketones										
Serum Sodium										
Serum Potassium										
Serum Chloride										
Serum Bicarbonate										
Urea										
Effective osmolality �										
Anion gap										
Blood Gases									1	
pH specify Venous (V) or Arterial (A)										
pO ₂										
pCO ₂										
SpO ₂										
Fluid/Metabolites (ml/hr)						1		1	I	
10% Glucose										
0.9% Normal Saline										
Potassium 10mmol/100ml										
Input						I.		I.	1	
IV (mL)										
Oral/NGT (mL)										
Output					[[[1	
Urine (mL)										
Other (mL)										
Other (specify)										
			LEGE	ND						
* A: Alert, D: Drowsy, S: Stuporous, C:	Comatose •	D: Dee		ow, N : Nor	mal	♦ [2 x N	a (mmol/L)] + [glucos	se (mmol/L	_)]



Queensland Government

SUPPLEMEN

IMMEDIATE MANAGEMENT

1. Acute Management of Diabetic Ketoacidosis in Adults

This protocol is for the acute management of diabetic ketoacidosis in patients 16 years and over.

WARNING: Due to the significant mortality that this condition carries, the following clinical signs would indicate the need for close monitoring. Always discuss these clinical signs and management decisions with senior team members.

- Respiratory Rate more than 20/min
- Pulse more than 90/min
- Systolic BP less than 100mmHg
- Circulatory compromise; pale, sweaty, cool or clammy peripheries - mottling indicates severe circulatory compromise

- Temp more than 38°C or less than 36°C Altered level of consciousness
- Consider central line

2. Signs of Cerebral Oedema

Children and adolescents are at the highest risk of cerebral oedema How will it present:

- Headaches
- Reduced conscious level
- How to take action:
- Monitoring for signs of cerebral oedema should start from the time of admission and continue up to at least 24 hours after admission
- Administer IV Mannitol (100mls of 20%) over 20 minutes or Dexamethasone 8mg (discuss with the Consultant)
- Undertake CT scan to confirm findings
- Consider ICU (an indication for checking arterial blood gases)

· If there is suspicion of cerebral oedema or the patient is not improving within 4 hours of admission. call the Consultant

3. Fluid Replacement

- Avoid using 0.45% (half normal) saline as there is no evidence to suggest that this is of benefit in the management of DKA
- Prescribed fluid resuscitation will meet the needs of people within the 50 - 90kg range. Fluids will need to be carefully reviewed and possibly modified if outside this weight range

4. Start Insulin

- Use any soluble insulin eg: Actrapid, Humulin R.
- Concentration should be 50 units of insulin in 49.5mLs 0.9% normal saline through a svringe driver

5. Other Interventions

Guidance on Bicarbonate:

There is no evidence to support the use of bicarbonate unless there is evidence of cardiogenic shock or other lactic acidgenerating conditions with markedly low pH <6.9. Must be given with Consultant authority Guidance on Phosphate:

There is no evidence to support the use of Phosphate replacement unless severe hypophosphatemia (more than 0.4mmol/L). Must be given with Consultant authority Guidance on Ketones:

Ketone testing is essential for diagnosis of DKA and can indicate effectiveness of management. Urine and blood ketone meters measure different ketones. Urine ketones may paradoxically rise initially and fall later but this does not mean treatment is ineffective. Urine ketones are cleared slowly. Blood ketones are more useful in monitoring progress.

Monitor blood ketones four hourly until ketone free. If not in DKA and with raised glucose levels recheck ketones in two hours

N	ITARY NOTES	
	ONGOING MANAGEMENT	CONTINUING CARE
	6. Reassess Patient, Monitor Vital Signs Potassium Replacement: Potassium should not be administered at a rate greater that 20mmol/hr except in the first 4 hours (maximum 40mmol/hr) without Consultant authority. Introduce Glucose: Glucose should be introduced in conjunction with 0.9% normal saline. Evidence for using 10% Glucose is lacking and mainly anecdotal. However, at this concentration, higher insulin levels can be maintained with enhanced clearance of ketones. It is not meant for	 10. Refer for Specialist Review Before Discharge Specialist Review: Some or all of the following professions should be part of the Diabetes Specialist Review Team; Diabetes Educator Dietitian Physician specialising in diabetes. Problems contributing to DKA Episode: Errors in insulin administration Faulty equipment
	re-hydration but glucose control 7. Further Monitoring, Continuation of Insulin <i>Laboratory Blood Glucose Testing:</i> While there is no specific evidence suggesting avoiding a rate of drop of blood glucose level of 5mmol/hr, there may be an increased risk of cerebral oedema if blood glucose levels drop too quickly. If blood glucose is less than 14mmol/L, the infusion rate of Glucose should be increased SUBSEQUENT MANAGEMENT	 Practical problems In patient presenting with DKA (especially recurrent DKA) there may be psycho-social issues requiring psychological support <i>Diabetes Education:</i> Some or all of the following aspects should be considered and discussed between the Diabetes Educator/Dietitian and patient: Revision of patient knowledge and understanding of the condition Review of "Sick Day Plan" Equipment – pens, syringes and pumps
	 8. Continuation of Intravenous Insulin Long acting (basal) subcutaneous insulin can be introduced in combination with intravenous insulin A point of care blood glucose meter can be used to monitor blood glucose level if the person is not peripherally shut down 9. Consider Precipitating Factors 	 Home blood glucose monitoring Diet All Medical Officers documenting on this protocol must sign the signature log on page 2
	Common causes include: • Omission of insulin • Infection • Newly diagnosed Diabetes Mellitus • Myocardial Infarction • Combination of the above	Feedback to: <u>sanglaK@health.qld.gov.au</u> Developed July 2009 Modfied October 2011 Next review October 2012